HHealthcare Read More My Top AI Healthcare Stock to Buy and Hold for 20 YearsJanuary 27, 2026 Eli Lilly has made several moves to boost its artificial intelligence (AI) capacity. It could help complement its…
MMedication Read More How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q4 Results?January 26, 2026 Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its…
HHealthcare Read More Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Buy in 2026January 26, 2026 Eli Lilly (NYSE: LLY) delivered a gain worthy of a technology growth stock last year. The pharma giant’s…
MMedication Read More Takeaways on turmoil surrounding FDA fast-track drug programJanuary 18, 2026 WASHINGTON (AP) — A plan to slash drug review times at the Food and Drug Administration is sparking…
MMedication Read More FDA commissioner’s drug review plan sparks alarmJanuary 17, 2026 WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored…
AArtificial intelligence Read More From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug developmentJanuary 16, 2026 Drug discovery, the art of identifying new molecules to develop pharmaceuticals, is a notoriously time-consuming and difficult process.…
AArtificial intelligence Read More From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug developmentJanuary 16, 2026 Credit: Chai Discovery | Image Credits:Chai Discovery Drug discovery, the art of identifying new molecules to develop pharmaceuticals,…
HHealthcare Read More Which Is the Better Stock Buy?January 16, 2026 Eli Lilly leads the weight loss market ahead of Novo Nordisk. Eli Lilly also has a more diversified…
MMedication Read More Eli Lilly’s Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain ReliefJanuary 16, 2026 Retatrutide’s recent trial results suggest it may be even better than Eli Lilly’s already approved GLP-1 medication, tirzepatide.…
MMedication Read More How Will Mounjaro and Zepbound Sales Aid LLY’s Upcoming Q4 Results?January 16, 2026 Eli Lilly LLY has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its…
HHealthcare Read More The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady GrowthJanuary 10, 2026 jetcityimage / iStock Editorial via Getty Images Lilly posted 53.9% revenue growth and 480% net income growth driven…
AArtificial intelligence Read More Schrodinger to offer Eli Lilly’s AI drug discovery platform on its softwareJanuary 9, 2026 By Sneha S K Jan 9 (Reuters) – Schrodinger said on Friday it is collaborating with Eli Lilly…